Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Status:
Terminated
Trial end date:
2019-12-05
Target enrollment:
Participant gender:
Summary
Participants will have been diagnosed with advanced progressive thyroid cancer and are about
to start treatment with a tyrosine kinase inhibitor (TKI).
The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase
inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes
papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid
cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive
(intermittent) versus conventional (continuous) regimen.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute